600196 复星医药
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入41,661,6131.45%41,399,54043,951,54739,011,18430,306,981
减:营业总成本40,087,3251.75%41,284,07741,346,26437,093,26628,594,719
    其中:营业成本20,800,103-2.65%21,595,30923,169,69020,229,78513,733,529
               财务费用1,153,4253.86%984,323647,403464,022724,273
               资产减值损失(150,063)55.39%(219,742)(272,488)(829,873)(148,254)
公允价值变动收益(322,268)177.96%(427,380)(2,498,368)352,299578,657
投资收益3,763,77878.84%3,501,9934,377,8434,623,8262,283,981
    其中:对联营企业和合营企业的投资收益1,923,97917.04%2,184,8491,835,1461,789,1371,580,335
营业利润5,228,35123.16%3,307,5084,656,6566,302,5684,721,145
利润总额5,111,98322.61%3,264,5684,574,3826,042,6714,677,844
减:所得税费用864,05431.55%369,504626,9171,066,401737,865
净利润4,247,93020.94%2,895,0633,947,4644,976,2693,939,980
减:非控股权益877,36818.16%508,798216,660247,559277,167
股东净利润3,370,56221.69%2,386,2663,730,8054,728,7113,662,813

市场价值指针
每股收益 (元) *1.27022.12%0.8901.4301.8501.430
每股派息 (元) *0.39021.88%0.2700.4200.5600.430
每股净资产 (元) *----17.11016.68415.29214.435
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容